In this open-label trial, a higher proportion of asymptomatic follicular lymphoma patients assigned to rituximab required no further treatment at nearly 15 years compared with those assigned to ...

This was an open-label, single-arm, single-center phase II study enrolling 40 patients. During the first week of the study, patients received two infusions of rituximab 375 mg/m 2 administered 4 days ...

The watchful waiting approach defers chemotherapy, on average, for about 2.5 years. This time was significantly increased in the new study in patients on rituximab — the median time to initiation of ...

Follicular lymphoma -- typically a slow-growing or indolent form of non-Hodgkin lymphoma that arises from B lymphocytes -- accounts for 20% to 30% of all non-Hodgkin lymphoma cases. The indolent ...

LONDON (Reuters) - Lymphoma patients who continue regular infusions of Genentech Inc and Biogen Idec's Rituxan after chemotherapy may live longer than patients who stop, Israeli researchers said on ...

First Phase 2 chemotherapy-free, lymphodepletion-free, off-the-shelf CAR-NK cell therapy plus ANKTIVA® and rituximab regimen to be evaluated in indolent non-Hodgkin lymphoma (iNHL), including ...

December 12, 2011 (San Diego, California) — For more than a decade now, rituximab (Rituxan, Genentech) has reigned supreme as the only drug of its kind — a monoclonal antibody specifically targeting ...